Circulating Tumor DNA as a Marker of Minimal Residual Disease
Cancer Network,
Ben Fangman, MD, and colleagues provide an overview of the use of circulating tumor DNA levels to detect minimal residual…
LBA30_PR Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
Overview of attention for article published in Annals of Oncology, October 2019
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (79th percentile)
-
Good Attention Score compared to outputs of the same age and source (74th percentile)
Readers on
- mendeley
- 61 Mendeley